- Home
- PLUG vs ADPT Comparison
PLUG vs ADPT Comparison
Compare PLUG & ADPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | PLUG | ADPT |
|---|---|---|
| Founded | 1997 | 2009 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.7B | 2.5B |
| IPO Year | 1999 | 2019 |
Fundamental Metrics
Financial Performance| Metric | PLUG | ADPT |
|---|---|---|
| Price | $2.21 | $16.17 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 13 | 10 |
| Target Price | $2.11 | ★ $16.60 |
| AVG Volume (30 Days) | ★ 92.8M | 2.8M |
| Earning Date | 11-10-2025 | 02-10-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $676,169,000.00 | $252,754,000.00 |
| Revenue This Year | $13.86 | $50.81 |
| Revenue Next Year | $21.99 | $1.17 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | 2.53 | ★ 42.57 |
| 52 Week Low | $0.69 | $5.96 |
| 52 Week High | $4.58 | $20.76 |
Technical Indicators
Market Signals| Indicator | PLUG | ADPT |
|---|---|---|
| Relative Strength Index (RSI) | 51.93 | 46.94 |
| Support Level | $1.92 | $16.05 |
| Resistance Level | $2.14 | $16.82 |
| Average True Range (ATR) | 0.16 | 0.60 |
| MACD | 0.00 | -0.03 |
| Stochastic Oscillator | 52.72 | 43.31 |
Price Performance
Historical ComparisonAbout PLUG Plug Power Inc.
Plug Power is building an end-to-end green hydrogen ecosystem—from production, storage, and delivery to energy generation. The company plans to build and operate green hydrogen highways across North America and Europe. Plug will deliver its green hydrogen solutions directly to its customers and through joint venture partners into multiple end markets, including material handling, e-mobility, power generation, and industrial applications.
About ADPT Adaptive Biotechnologies Corporation
Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).